Paul Stockhammer, MD, PhD
Clinical FellowAbout
Research
Publications
2026
ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
Stockhammer P, El Zarif T, Schillo JL, Li F, Goldberg SB, Politi K, Grant MJ. ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. J Thorac Oncol 2026, 103708. PMID: 41932614, DOI: 10.1016/j.jtho.2026.103708.Peer-Reviewed Original Research
2025
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
Di Federico A, Wang K, Chen M, Barsouk A, Pagliaro A, Chen L, Ogliari F, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton G, Citarella F, Meyer D, Aldea M, De Giglio A, Alessi J, Pecci F, Gelsomino F, Corassa M, Vokes N, Wang X, de Biase D, Abu Rous F, Areesawangkit P, Elghawy O, Cortellini A, Metro G, Ferrara R, Awad M, Pabani A, Murray J, Cappuzzo F, Garassino M, Dagogo-Jack I, Riely G, Grant M, Herzberg B, Ardizzoni A, Planchard D, Johnson B, Langer C, Offin M, Negrao M, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF V600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. The Lancet Oncology 2025, 26: 1357-1369. PMID: 41038185, DOI: 10.1016/s1470-2045(25)00409-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansImmune Checkpoint InhibitorsImmunotherapyLung NeoplasmsMaleMiddle AgedMitogen-Activated Protein Kinase KinasesMutationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRetrospective StudiesConceptsNon-small-cell lung cancerImmune checkpoint inhibitorsFirst-line immune checkpoint inhibitorsMitogen-activated protein kinase inhibitorMedian overall survivalOverall survivalHistory of smokingRetrospective cohort studyMitogen-activated protein kinaseAssociated with longer median overall survivalMetastatic non-small-cell lung cancerLung cancerPD-L1 tumor proportion scoreCohort studyEastern Cooperative Oncology Group performance statusHigher PD-L1 expressionLonger median overall survivalFirst-line immunotherapyFrequency of adverse eventsTP53 co-mutationsTreated with BRAFPD-L1 expressionTumor proportion scoreSecond-line therapyFirst-line therapyFirst-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study.
Di Federico A, Wang K, Chen M, Barsouk A, Pagliaro A, Chen L, Ogliari F, Stockhammer P, Thawani R, Raslan S, Gariazzo E, Fusco F, Hambelton G, Citarella F, Meyer D, Corassa M, Langer C, Offin M, Negrao M, Ricciuti B. First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. Journal Of Clinical Oncology 2025, 43: 8574-8574. DOI: 10.1200/jco.2025.43.16_suppl.8574.Peer-Reviewed Original ResearchTP53 co-mutationsTumor proportion scoreShorter mPFSCo-mutationsBRAF V600EMEK inhibitorsPD-L1 tumor proportion scoreMetastatic non-small cell lung cancerNon-small cell lung cancerHistory of tobacco smokingFirst-line immunotherapyMedian overall survivalSubgroups of ptsTreated with BRAFProgression-free survivalRate of adverse eventsWild-type TP53Cell lung cancerHistory of smokingTobacco smoking historyScore-matched cohortWild-type IDH1PD-L1Brain metastasesLine therapyPP01.07 Alterations in Tumor Suppressor Genes are Associated With Aggressive Disease Phenotypes in EGFR-Mutant NSCLC
Stockhammer P, Sweeney K, Liu S, Halmos B, Uprety D, Elliott A, VanderWalde A, Politi K, Goldberg S, Grant M. PP01.07 Alterations in Tumor Suppressor Genes are Associated With Aggressive Disease Phenotypes in EGFR-Mutant NSCLC. Journal Of Thoracic Oncology 2025, 20: s5. DOI: 10.1016/j.jtho.2025.03.015.Peer-Reviewed Original Research
2024
1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
Di Federico A, Chen M, Pagliaro A, Ogliari F, Stockhammer P, Aldea M, Grant M, De Giglio A, Alessi J, Pecci F, Gelsomino F, Negrao M, Ferrara R, Awad M, Riely G, Ardizzoni A, Planchard D, Offin M, Johnson B, Ricciuti B. 1299P First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer. Annals Of Oncology 2024, 35: s826-s827. DOI: 10.1016/j.annonc.2024.08.1356.Peer-Reviewed Original ResearchComprehensive characterization of ERBB2 genomic alterations inlung cancer.
El Zarif T, Stockhammer P, Schillo J, Goldberg S, Politi K, Grant M. Comprehensive characterization of ERBB2 genomic alterations inlung cancer. Journal Of Clinical Oncology 2024, 42: 3148-3148. DOI: 10.1200/jco.2024.42.16_suppl.3148.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalShorter progression-free survivalTyrosine kinase domainSystemic therapyCo-mutationsClinical characteristics of non-small cell lung cancerCharacteristics of non-small cell lung cancerFirst-line platinum-based chemotherapyMedian tumor mutation burdenNon-small cell lung cancer tumorsFirst-line systemic therapyTP53 co-mutationsPlatinum-based chemotherapyTumor mutational burdenKaplan-Meier methodCell lung cancerLog-rank testOptimal treatment strategyHistory of smokingCopy number profilesTumor profile dataJuxtamembrane domainSquamous histologyTrastuzumab deruxtecanERBB2 mutations and association with molecular phenotype in urothelial carcinoma.
Machaalani M, El Zarif T, Stockhammer P, Semaan K, Eid M, El Hajj Chehade R, Nawfal R, Yekeduz E, Nassar A, Lee G, Baca S, CHOUEIRI T, Grant M, Bellmunt J. ERBB2 mutations and association with molecular phenotype in urothelial carcinoma. Journal Of Clinical Oncology 2024, 42: 4590-4590. DOI: 10.1200/jco.2024.42.16_suppl.4590.Peer-Reviewed Original ResearchUpper tract UCTumor mutational burdenUrothelial carcinomaERBB2-targeted therapyMutant tumorsUC tumorsERBB2 amplificationMedian tumor mutation burdenHigh tumor mutational burdenWild type tumorsChi-square and Mann-Whitney U testsCombination therapy studiesMolecular phenotypesMann-Whitney U testTumor profile dataERBB2 mutationsBladder UCPolyPhen-2Mutational burdenType tumorsGenomic dataSolid tumorsClinical characteristicsCo-mutationsActivating mutationsEfficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review
Grant M, Stockhammer P, Austin M, Nemeth Z, Petrylak D. Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review. Bladder Cancer 2024, 10: 9-23. PMID: 38993528, PMCID: PMC11181835, DOI: 10.3233/blc-230070.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaAntibody-drug conjugatesClinical trialsUrothelial carcinomaCombination regimensDrug conjugatesSystematic reviewAnti-PD-1 agentsProspective therapeutic clinical trialsCochrane Central TrialsClinical trial cohortObjective response rateTherapeutic clinical trialsMeta-Analyses (PRISMA) statementNon-duplicated articlesPreferred Reporting ItemsComprehensive systematic reviewPotent cytotoxic payloadTrial cohortEnfortumab vedotinOvid EmbaseSacituzumab govitecanADC targetImpressive efficacyOvid MEDLINE
2023
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Zhao H, Choi J, Chung S, Li F, Walther Z, Dietz J, Duffield E, Gettinger S, Politi K, Goldberg S. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Journal Of Thoracic Oncology 2023, 19: 240-251. PMID: 37806385, PMCID: PMC11364167, DOI: 10.1016/j.jtho.2023.10.001.Peer-Reviewed Original ResearchProgression-free survivalEGFR-mutant NSCLCTP53 mutationsOverall survivalClinical outcomesEGFR-TKIInferior outcomesWorse outcomesYale cohortMetastatic EGFR-mutant NSCLCShorter progression-free survivalEGFR-mutant lung cancerTyrosine kinase inhibitor therapyFirst-line TKIYale Cancer CenterSecond-line therapyInferior clinical outcomesSubset of patientsKinase inhibitor therapyAdditional therapeutic interventionsAggressive disease phenotypeCo-occurring alterationsTumor suppressor gene alterationsTumor genomic profilingMultiple tumor suppressor genesKrebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma
Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Lung Cancer 2023, 185: 107360. PMID: 37713954, DOI: 10.1016/j.lungcan.2023.107360.Peer-Reviewed Original ResearchKrebs von den Lungen-6KL-6 levelsPleural mesotheliomaIndependent validation cohortPM patientsPrognostic biomarkerLungen-6Overall survivalValidation cohortPrimary cell linesHigher KL-6 levelsLower KL-6 levelsChemiluminescence enzyme immunoassayPleural effusion levelsSystemic treatment optionsBetter overall survivalNon-malignant controlsPleural effusion samplesCell line supernatantsMucin-1 glycoproteinCell linesMUC1 mRNA expressionEffusion levelsPleural disordersConsecutive patients